ZACKS RESEARCH

FUNDS

PORTFOLIO

BROKER RESEARCH

MARKETS

SCREENING

EDUCATION

SERVICES

Earnings

EPS Surprises

Mutual Funds

Options

My Account

Help

Zacks Education
Visit Zacks' Education section for investing guides and other free resources to make you a better investor.

Quote:

Search for Ticker

Free Membership

Search:

GILD: Gilead Sciences Inc - Full Company Report Enter Ticker:

Quote	Estimates	Charts	Company Reports	News	Financials

Full Company Report \| Estimates \| Brokerage Recommendations \| Comparison to Industry \| Insiders \| Brokerage Reports \| Zacks Equity Research \| Annual Report

GILEAD SCIENCES INC (NASD)
GILD	46.96	N/A	(N/A%)	Vol. 0	N/A ET

Gilead Sciences, Inc. is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them. They have a broad-based focus on developing and marketing drugs to treat patients with infectious diseases, including viral infections, fungal infections and bacterial infections, and a specialized focus on cancer. They have expertise in liposomal drug delivery technology, a technology that the company uses to develop drugsthat are safer, easier for patients to tolerate and more effective.

General Information

GILEAD SCIENCES

333 Lakeside Drive Foster City, CA 94404 Phone: 650-574-3000 Fax: 650-578-9264 Web: www.gilead.com Email: investor_relations@gilead.com

Industry	MED-BIOMED/GENE
Sector:	Medical

Fiscal Year End	December
Last Reported Quarter	09/30/09
Next EPS Date	01/26/2010

Price and Volume Information

Zacks Rank
Yesterday's Close	46.96
52 Week High	53.28
52 Week Low	40.62
Beta	0.45
20 Day Moving Average	7,719,846.50
Target Price Consensus	55.35

% Price Change
4 Week	5.84
12 Week	2.52
YTD	-9.29

% Price Change Relative to S&P 500
4 Week	4.70
12 Week	-3.35
YTD	-24.92

Share Information
Shares Outstanding (millions)	904.26
Market Capitalization (millions)	41,948.67
Short Ratio	2.24
Last Split Date	06/25/2007

Dividend Information
Dividend Yield	0.00%
Annual Dividend	$0.00
Payout Ratio	0.00
Change in Payout Ratio	0.00
Last Dividend Payout / Amount	NA / $0.00

EPS Information
Current Quarter EPS Consensus Estimate	0.79
Current Year EPS Consensus Estimate	2.76
Estimated Long-Term EPS Growth Rate	15.90
Next EPS Report Date	01/26/2010

Consensus Recommendations
Current (1=Strong Buy, 5=Strong Sell)	1.43
30 Days Ago	1.41
60 Days Ago	1.38
90 Days Ago	1.33

Fundamental Ratios

P/E
Current FY Estimate:	16.84
Trailing 12 Months:	17.71
PEG Ratio	1.06

EPS Growth
vs. Previous Year	42.31%
vs. Previous Quarter	13.85%

Sales Growth
vs. Previous Year	31.37%
vs. Previous Quarter:	9.36%

Price Ratios
Price/Book	7.29
Price/Cash Flow	19.91
Price / Sales	6.55

ROE
09/30/09	48.58
06/30/09	48.64
03/31/09	49.32

ROA
09/30/09	30.85
06/30/09	30.34
03/31/09	30.10

Current Ratio
09/30/09	2.27
06/30/09	2.25
03/31/09	3.66

Quick Ratio
09/30/09	1.74
06/30/09	1.71
03/31/09	2.92

Operating Margin
09/30/09	38.36
06/30/09	37.94
03/31/09	37.61

Net Margin
09/30/09	49.51
06/30/09	49.82
03/31/09	50.65

Pre-Tax Margin
09/30/09	49.51
06/30/09	49.82
03/31/09	50.65

Book Value
09/30/09	6.36
06/30/09	5.86
03/31/09	5.51

Inventory Turnover
09/30/09	1.50
06/30/09	1.43
03/31/09	1.35

Debt-to-Equity
09/30/09	0.21
06/30/09	0.22
03/31/09	0.23

Debt to Capital
09/30/09	17.06
06/30/09	18.13
03/31/09	18.42


About Zacks \| Advertise \| Media \| Careers \| Contact Us \| Help Disclaimer \| Privacy Policy \| Sitemap NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed. Copyright 2009 Zacks Investment Research